{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Number and percentage of participants with CD4 and/or CD8 immune responses against WT1m measured 12-14 weeks after first GPS administration (6 x administrations)","groups":[{"description":"Galinpepimut-S (GPS) vaccinations are started 12-22 days following autologous stem cell transplantation (ASCT). GPS and Montanide (in a 1 mL emulsion) are administered subcutaneously (s.c.) Q2W on weeks 0, 2, 4, 6, 8, and 10. GM-CSF (70 μg) are administered s.c. one to two days before and on the day of GPS/Montanide administration. Participants whose disease has not progressed and who are clinically stable (no active infection with fevers and no cardiovascular/respiratory compromise) may receive up to 6 additional monthly vaccinations. The use of post-ASCT maintenance therapy is allowed starting 3 months after ASCT.\n\nGalinpepimut-S: Galinpepimut-S admixed with the adjuvant Montanide following specified schedule\n\nGM-CSF: subcutaneous injection\n\nMontanide: adjuvant\n\nlenalidomide: optional post-ASCT therapy\n\nbortezomib: optional post-ASCT therapy","id":"OG000","title":"Galinpepimut-S + Montanide + GM-CSF"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only 15 patients completed 6 x GPS administrations","reportingStatus":"POSTED","timeFrame":"12 weeks after the initial GPS vaccine (end of first series [GPS x 6 administrations])","title":"WT1 T-cell Immune Response (IR) 12-14 Weeks After First GPS Administration (6 x Administrations)","type":"PRIMARY","unitOfMeasure":"Participants"}